SOD1 and amyotrophic lateral sclerosis: Thus, we formed a discovery cohort (of responder patients) by selecting the 9 SOD1‐ALS individuals from the group of patients previously recruited in the German EAP who showed the most pronounced reduction of CSF and serum neurofilament upon tofersen therapy (Table S1).5